Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Holger N. Lode, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Canete, John Anderson, Isaac Yaniv, Shifra Ash, Juliet Gray, Thomas Klingebiel, Hans Loibner, Roberto Luksch, Carla Manzitti, Jean Marie Michon, Cormac Owens, Ulrike Pötschger, Sascha Troschke-Meurer, Evgenia Glogova, Ruth Ladenstein, Unknown

Open source

DOI: 10.1158/1078-0432.ccr-25-0180
Published: 2025-07-08
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-0180,
  title = {Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial},
  author = {Holger N. Lode and Nikolai Siebert and Dominique Valteau-Couanet and Alberto Garaventa and Adela Canete and John Anderson and Isaac Yaniv and Shifra Ash and Juliet Gray and Thomas Klingebiel and Hans Loibner and Roberto Luksch and Carla Manzitti and Jean Marie Michon and Cormac Owens and Ulrike Pötschger and Sascha Troschke-Meurer and Evgenia Glogova and Ruth Ladenstein and Unknown},
  year = {2025},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-0180},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-0180}
}

RIS

TY  - JOUR
TI  - Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
AU  - Holger N. Lode
AU  - Nikolai Siebert
AU  - Dominique Valteau-Couanet
AU  - Alberto Garaventa
AU  - Adela Canete
AU  - John Anderson
AU  - Isaac Yaniv
AU  - Shifra Ash
AU  - Juliet Gray
AU  - Thomas Klingebiel
AU  - Hans Loibner
AU  - Roberto Luksch
AU  - Carla Manzitti
AU  - Jean Marie Michon
AU  - Cormac Owens
AU  - Ulrike Pötschger
AU  - Sascha Troschke-Meurer
AU  - Evgenia Glogova
AU  - Ruth Ladenstein
AU  - Unknown
PY  - 2025
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-25-0180
UR  - https://doi.org/10.1158/1078-0432.ccr-25-0180
ER  -

APA

Lode, H. N., Siebert, N., Valteau-Couanet, D., Garaventa, A., Canete, A., Anderson, J., Yaniv, I., Ash, S., Gray, J., Klingebiel, T., Loibner, H., Luksch, R., Manzitti, C., Michon, J. M., Owens, C., Pötschger, U., Troschke-Meurer, S., Glogova, E., Ladenstein, R., & Unknown (2025). Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-0180

Source records

crossref · retrieved 2026-09-27T18:49:36.991Z